Asset profile
Forimtamig
Multispecific antibody
Evidence outlook
Phase 1/2 study terminated, no active studies registered
The furthest-phase study registered for this program (NCT06055075) was terminated, and no study is currently active on the registry. Earlier completed evidence carries a weak signal signal; the stopped study adds none. Check the registry record for the sponsor's stated reason.
NCT04557150: This was an open-label, single-arm dose-escalation study with no control group and no blinding, designed to establish safety and dosing rather than to compare forimtamig against another treatment. Without a comparator arm or posted results, this design cannot support a positive-efficacy conclusion.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
64 competitors in this universe: 4 direct rivals (same mechanism and indication), 0 same-class, 60 same-indication; 61 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Forimtamig: this drug | Phase 1/2 | Multispecific antibody | GPRC5D x CD3 | ||
| Talquetamab | Approved | Multispecific antibody | GPRC5D x CD3 | ||
| QLS32015 | Phase 3 | Multispecific antibody | GPRC5D x CD3 | ||
| LBL-034 | Phase 1/2 | — | GPRC5D x CD3 | ||
| TQB2029 | Phase 1 | Multispecific antibody | GPRC5D x CD3 | ||
| Belantamab Mafodotin | Approved | Antibody–drug conjugate | BCMA | ||
| Bortezomib | Approved | Small molecule | Proteasome | ||
| Carfilzomib | Approved | Small molecule | Proteasome | ||
| Ciltacabtagene Autoleucel | Approved | Cell therapy | BCMA | ||
| Daratumumab | Approved | Monoclonal antibody | CD38 | ||
| Denosumab | Approved | Monoclonal antibody | RANKL | ||
| Elotuzumab | Approved | Monoclonal antibody | SLAMF7 (CS1/CD319) | ||
| Elranatamab | Approved | Multispecific antibody | BCMA x CD3 | ||
| Idecabtagene Vicleucel | Approved | Cell therapy | BCMA | ||
| Isatuximab | Approved | Monoclonal antibody | CD38 | ||
| Ixazomib | Approved | Small molecule | Proteasome |
…and 49 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.